Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 As Monotherapy and in Combination Therapy in Participants with Advanced Solid Malignancies

Next Previous
Search
Trial Profile

A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 As Monotherapy and in Combination Therapy in Participants with Advanced Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GS 0321 (Primary) ; Zimberelimab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Compugen

    • Most Recent Events

    • 08 Jan 2025 According to a Compugen Ltd. media release, company announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead.
    • 29 Jul 2024 According to a Compugen Ltd. media release, In 2023, Compugen and Gilead entered into a license agreement, pursuant to which Gilead was granted exclusive rights to develop and commercialize, COM503. The FDA IND clearance for COM503 triggers a $30 million milestone payment from company's partner Gilead to initiate Phase 1 trial.
    • 29 Jul 2024 According to a Compugen Ltd. media release, U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate Phase 1 trial for COM503 in solid tumors, in the fourth quarter of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top